Literature DB >> 20689326

Increased ACE and decreased ACE2 expression in kidneys from patients with IgA nephropathy.

Sonoo Mizuiri1, Hiromichi Hemmi, Michitsune Arita, Toshiyuki Aoki, Yasushi Ohashi, Moriatsu Miyagi, Ken Sakai, Kazutoshi Shibuya, Hiroki Hase, Atsushi Aikawa.   

Abstract

BACKGROUND: Angiotensin-converting enzyme (ACE)2 forms angiotensin-1-7 which may protect kidney in a counterregulatory manner to angiotensin II. Recent studies revealed increased ACE and decreased ACE2 expression in kidneys of patients with diabetic nephropathy. However, these changes may not be specific for diabetic nephropathy. We studied ACE and ACE2 expression in patients with IgA nephropathy.
METHODS: Renal ACE and ACE2 expression was assessed by immunohistochemistry and in situ hybridization in 30 patients with IgA nephropathy and 21 healthy controls. Correlation between ACE and ACE2 expression and levels of various biochemical parameters was also assessed. Gene expression was also assessed in minimal change nephrotic syndrome (MCNS) and membranous nephropathy (MN) as disease controls.
RESULTS: Reduced ACE2 expression (p < 0.01) and increased ACE expression in glomeruli (p < 0.001), and reduced ACE2 expression in tubulointerstitium (p < 0.001) were observed in patients with IgA nephropathy compared to healthy controls, although the changes in ACE2 mRNA were not statistically significant. Reduced renal ACE2 expression was also found in MN but not in MCNS. Correlation between renal ACE and ACE2 expression and proteinuria was not observed in IgA nephropathy.
CONCLUSION: IgA nephropathy is associated with increased ACE and decreased ACE2 expression in kidneys, as in diabetic nephropathy.
Copyright © 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20689326     DOI: 10.1159/000319648

Source DB:  PubMed          Journal:  Nephron Clin Pract        ISSN: 1660-2110


  17 in total

Review 1.  The renin-angiotensin-aldosterone system in 2011: role in hypertension and chronic kidney disease.

Authors:  Ana Cristina Simões E Silva; Joseph T Flynn
Journal:  Pediatr Nephrol       Date:  2011-09-23       Impact factor: 3.714

Review 2.  ACE and ACE2 in kidney disease.

Authors:  Sonoo Mizuiri; Yasushi Ohashi
Journal:  World J Nephrol       Date:  2015-02-06

Review 3.  ACE2 alterations in kidney disease.

Authors:  María José Soler; Jan Wysocki; Daniel Batlle
Journal:  Nephrol Dial Transplant       Date:  2013-08-16       Impact factor: 5.992

4.  Enzymatic processing of angiotensin peptides by human glomerular endothelial cells.

Authors:  Juan Carlos Q Velez; Jessalyn L Ierardi; Alison M Bland; Thomas A Morinelli; John M Arthur; John R Raymond; Michael G Janech
Journal:  Am J Physiol Renal Physiol       Date:  2012-03-28

Review 5.  ACE2, angiotensin-(1-7) and Mas receptor axis in inflammation and fibrosis.

Authors:  A C Simões e Silva; K D Silveira; A J Ferreira; M M Teixeira
Journal:  Br J Pharmacol       Date:  2013-06       Impact factor: 8.739

6.  Angiotensin converting enzyme 2, Angiotensin-(1-7), and receptor MAS axis in the kidney.

Authors:  Sergio Veloso Brant Pinheiro; Ana Cristina Simões E Silva
Journal:  Int J Hypertens       Date:  2012-02-08       Impact factor: 2.420

Review 7.  Involvement of glomerular renin-angiotensin system (RAS) activation in the development and progression of glomerular injury.

Authors:  Shoji Kagami
Journal:  Clin Exp Nephrol       Date:  2011-12-02       Impact factor: 2.801

8.  Intrarenal distributions and changes of Angiotensin-converting enzyme and Angiotensin-converting enzyme 2 in feline and canine chronic kidney disease.

Authors:  Sawane Mitani; Akira Yabuki; Mariko Sawa; Hye-Sook Chang; Osamu Yamato
Journal:  J Vet Med Sci       Date:  2013-09-05       Impact factor: 1.267

9.  Granuloma of the labial minor salivary glands in tuberculosis.

Authors:  Adriana Handra-Luca
Journal:  J Oral Maxillofac Pathol       Date:  2018 Jan-Apr

Review 10.  ACE2: angiotensin II/angiotensin-(1-7) balance in cardiac and renal injury.

Authors:  Jasmina Varagic; Sarfaraz Ahmad; Sayaka Nagata; Carlos M Ferrario
Journal:  Curr Hypertens Rep       Date:  2014-03       Impact factor: 5.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.